Human medicines European public assessment report (EPAR): Mayzent, siponimod, Multiple Sclerosis, Relapsing-Remitting, Date of authorisation: 13/01/2020, Revision: 4, Status: Authorised

SEMrush
Human medicines European public assessment report (EPAR): Mayzent, siponimod, Multiple Sclerosis, Relapsing-Remitting, Date of authorisation: 13/01/2020, Revision: 4, Status: Authorised
[automaticbacklinks]